[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9605503A - Improved modified live brsv vaccine. - Google Patents

Improved modified live brsv vaccine.

Info

Publication number
MX9605503A
MX9605503A MX9605503A MX9605503A MX9605503A MX 9605503 A MX9605503 A MX 9605503A MX 9605503 A MX9605503 A MX 9605503A MX 9605503 A MX9605503 A MX 9605503A MX 9605503 A MX9605503 A MX 9605503A
Authority
MX
Mexico
Prior art keywords
immunity
adjuvant
brsv
modified live
polyoxypropylene
Prior art date
Application number
MX9605503A
Other languages
Spanish (es)
Other versions
MXPA96005503A (en
Inventor
Hsien-Jue Chu
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Priority claimed from PCT/US1995/006053 external-priority patent/WO1995030437A1/en
Publication of MXPA96005503A publication Critical patent/MXPA96005503A/en
Publication of MX9605503A publication Critical patent/MX9605503A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides an improved BRSV vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises a modified live BRS virus and an adjuvant, which in combination provide immunity from BRSV infection after a single administration, and elicit an immune response specific to BRSV and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the BRS virus is strain 375, and the adjuvant comprises an unsaturated turpin hydrocarbon, preferably squalene or squalane, and a polyoxypropylene-polyoxyethylene block copolymer, most preferably one where the copolymer has a polyoxypropylene (POP) component with an average molecular weight of about 3250 to 4000 and the polyoxyethylene (POE) component comprises about 10-20 percent of the total molecule. The adjuvant may optionally include a surfactant, preferably a polyoxyethylenesorbitan monooleate.
MX9605503A 1995-05-08 1995-05-08 Improved modified live brsv vaccine. MX9605503A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US240,373 1994-05-10
US240373 1994-05-10
PCT/US1995/006053 WO1995030437A1 (en) 1994-05-10 1995-05-08 Improved modified live brsv vaccine

Publications (2)

Publication Number Publication Date
MXPA96005503A MXPA96005503A (en) 1998-02-01
MX9605503A true MX9605503A (en) 1998-02-28

Family

ID=39165112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605503A MX9605503A (en) 1995-05-08 1995-05-08 Improved modified live brsv vaccine.

Country Status (1)

Country Link
MX (1) MX9605503A (en)

Similar Documents

Publication Publication Date Title
MY111829A (en) Modified live brsv vaccine
WO2004058142A3 (en) Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses
MY129765A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
CA2201598A1 (en) Vaccine compositions
AU1234697A (en) Streptococcus equi vaccine
DK1053017T3 (en) Vaccines comprising interleukin-12 and herpes simplex virus antigen
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
GEP20053446B (en) Adjuvant Combination Formulations
Kaminski et al. Mucosal adjuvant properties of the Shigella invasin complex
MX9605503A (en) Improved modified live brsv vaccine.
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
Chu Modified live BRSV vaccine
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
CA2348658A1 (en) Vaccine preparations containing attenuated toxin
Donnelly New developments in adjuvants
Wasserman et al. Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect
WO1996039113A3 (en) Oral administration of pneumococcal antigens
AU8144194A (en) Vaccine against mumps containing a jeryl-lynn virus strain
Ronco et al. Adjuvants for mucosal vaccines
WO2000003731A3 (en) Vaccine to prevent and treat chlamydial infections
WO2001002005A3 (en) Treatment of dentritic cells for induction of immune tolerance